Adline Chem Lab Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Adline Chem Lab Ltd is ₹ 11.28 as of 20 Apr 15:30 . The P/E Ratio of Adline Chem Lab Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Adline Chem Lab Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Adline Chem Lab Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Adline Chem Lab Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Adline Chem Lab Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Adline Chem Lab Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Adline Chem Lab Ltd

Adline Chem Lab Limited (Formerly known as Kamron Laboratories Limited) was incorporated in 1988 by its Promoter, Mr Kamlesh J Laskari.
The Company name was changed from Kamron Laboratories Limited' to Adline Chem Lab Limited effective on October 13, 2021.
Adline is a dynamic and innovative multinational company specializing in providing integrated solutions and services across diverse industries.
It is engaged in manufacturing of pharmaceutical chemicals, fine chemicals, agrochemical products.
ADLINE's mission is to revolutionize the industries it serves by providing unparalleled excellence in chemicals, laboratory and lab products establishment, active pharmaceutical ingredients (API), pharmaceuticals, agro/agro trade, biotech, and fertilizers. In May 1990, the Company started production at its site in Rakanpur, Gujarat.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Adline Chem Lab Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Adline Chem Lab Ltd or Sanofi India Ltd?

Market cap of Adline Chem Lab Ltd is 6 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Adline Chem Lab Ltd and Sanofi India Ltd?

The stock performance of Adline Chem Lab Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Adline Chem Lab Ltd and Sanofi India Ltd?

As of May 3, 2026, the Adline Chem Lab Ltd stock price is INR ₹11.28. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Adline Chem Lab Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Adline Chem Lab Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.